🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Andrew Moon Laura Dawson AASLD ILTS It is time to consider external radiotherapy as an alternative to local destruction in small HCC in EASLnews BCLC GROUP guidelines notably in small and superficial HCC closed to the diaphragm...

What did @dianajonescm learn @ #caregiver interventions in #HGG #BTSM #BrainTumour in her #SysRev ? #Surv23 #SuppOnc ⁦Mark Pinkham⁩ #BRAINs ⁦POCOG⁩ ⁦@HelenHaydon⁩

We finish our #IWD2023 celebration honouring the work and contribution of A/Prof Mei Ling Yap. Thank you A/Prof Yap. Thank you to all the extraordinary #WomenInRadiology and #WomenRadOnc for your scientific work and commitment to patient care. #EmbraceEquity

📢 This is a super cool 🤗 recognition of years of work from Peter Mac Radiation Oncology, GU Cast | Urology podcast! and PAH team led by David Pryor! Link to paper: bit.ly/423LA6g Gutted to not be at #EAU2023 to receive this award; lucky the preternaturally media savvy Declan Murphy was! jim catto

The CORE oligometastatic SBRT trial will be presented at #ESTRO23. - signal finding trial with p at 0.2 - SOC vs SOC+SBRT - prostate, breast and lung Ca - 6 months PFS advantage of adding SBRT to SOC. ⁦Chad Tang, MD⁩ ⁦Shankar Siva⁩ ⁦Matthias Guckenberger estro.org/Congresses/EST…

Local ablation is curative treatment for those who are ineligible for surgical therapies, particularly if lesion <3 cm in size. #Radioembolization (using radiation segmentectomy approach) and external beam radiation therapy (#EBRT) can be alternative approaches to local ablation

Clinical Trials Day is an opportunity to raise awareness about the importance of #clinicaltrials. Today TROG reflects on our research achievements and to look ahead to our ASM, where we honour and celebrate clinical trials. Register for our ASM here: asm.trog.com.au

Great news: enzalutamide now available in Australia on PBS for met hormone-sensitive #ProstateCancer. Direct result of amazing contributions to ANZUP #ENZAMET trial by participants, investigators, NHMRC CTC CCTG CancerTrialsIreland 🌈 Dana-Farber. Thanks to all!

Breaking a decade of silence. As the ONLY trainee to win in criminal court against a senior doctor, I’ve seen the system betray victims. Abusers hide behind status quo, we must demand change 🙏🏻 C Begeny + team James Gallagher BBC News (UK) #MeTooMedicine www-bbc-co-uk.cdn.ampproject.org/c/s/www.bbc.co…

How would you like to offer men with #prostatecancer a treatment proven to have ~95% disease control at 5 years? Results of our prospective multicentre PROMETHEUS clinical trial now out in European Urology Oncology. Open access link here, and breakdown in thread. sciencedirect.com/science/articl…

Insightful cost-effectiveness analysis here of SC24, the landmark randomized study of spine SBRT (24 Gy/2) versus conventional RT. Bottom-line: in the Canadian healthcare system, SBRT is clearly, obviously, cost-effective. arjun sahgal sciencedirect.com/science/articl…

1/ For #KidneyCancerAwareness month The Lancet Oncology has a 50-day full link to TROG Cancer Research FASTRACK II! authors.elsevier.com/a/1ifvZ5EIIgPd…. Thank you Cancer Australia, ANZUP, Varian. A new #radiotherapy standard of care option for inoperable primary #kidneycancer #radonc

2/ Excitingly, 100% control rates despite a median size of 4.6cms, and biological aggressiveness with 70% progressing on surveillance (imaging) prior to enrolment. Despite this, recent @uroweb #EAUguidelines confusingly lump TA and SABR together… and caution treating >3cm! 🧐

3/ There are >dozen clinical trials of SABR for primary RCC – outlined in ISRSy practice guideline - shorturl.at/suPTW – compared to zero for thermal ablation. The weight of evidence is with SABR, not TA, and is arguably the preferred modality for non-surgical therapy

4/ Very excited to share this with you!!! Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Brian Shuch, MD Grant Stewart Phillip Pierorazio Todd 〽️ Morgan, MD Alexander Kutikov MD Sarah P. Psutka MD MS Michael Staehler IKCC Kidney Cancer Kidney Cancer For more information, please follow the thread from Astro 2023. x.com/_ShankarSiva/s…

NEW The TROG 15.03 FASTRACK II non-randomised phase 2 trial investigated the efficacy of stereotactic ablative body radiotherapy for primary renal cell cancer. #rccsm #radonc thelancet.com/journals/lanon…

SABR Leads to Local Control in Primary RCC Without Surgery The Lancet Shankar Siva @petermaccc #kcsm #oncology onclive.com/view/sabr-lead…

🔦 Spotlight on TROG 21.07 SOCRATES HCC! The trial aims to explore whether Stereotactic Ablative Body Radiotherapy (SABR) can surpass conventional methods like thermal ablation (MWA/RFA)& transarterial therapies (TACE/TARE). For more info visit: trog.com.au/trials/trog-21…

Brachytherapy doses of radiotherapy delivered non-invasively for prostate cancer with 94.1% 5-year control and low rates of significant toxicity. Now being investigated in randomised trials such as Trans Tasman Radiation Oncology Group NINJA and GETUG PEACE 7.

Congrats to TROG 21.07 – SOCRATES HCC researchers on opening all 20 Australian sites for the study investigating if stereotactic ablative body radiotherapy (SABR) could offer a safer, more effective treatment for early-stage hepatocellular cancer. hubs.ly/Q039lT-s0